Treatment response and eating behavior patterns with GLP-1/GIP co-receptor agonists

Observational Study of the Therapeutic Effects of Switching from GLP-1 Receptor Agonists to GLP-1/GIP Co- Receptor Agonists: Relationship to Patients' Eating Behavior Patterns

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041230070

Enrollment

Registered

2023-08-18

Start date

2023-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Diabetes

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who have been switched from a GLP-1 receptor agonist to a GLP-1/GIP co-receptor agonist, who understand the purpose of the study and give their consent

Exclusion criteria

Exclusion criteria: 1) Patients who have difficulty following the instructions of the principal investigator or sub-investigator 2) Other patients who are deemed inappropriate for this study by the principal investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
HbA1c change from baseline to 12 weeks after treatment based on food preferences and eating behavior	—

Secondary

Measure	Time frame
Based on food preferences and eating behavior, Percentage of patients achieving target HbA1c at 12 and 52 weeks Percentage of patients achieving HbA1c <7.0% at Weeks 12 and 52 Weight change from baseline to Week 12,52 Body composition change from baseline to Week 12,52 Change in grip strength from baseline to Week 12,52 Change in total energy intake and intake of the three macronutrients (FFQ) from baseline to Weeks 12 and 52 Change in urinary albumin (or urinary protein if diabetic nephropathy stage 3 or later) from baseline to Weeks 12 and 52	—

Measure

Time frame

Based on food preferences and eating behavior, Percentage of patients achieving target HbA1c at 12 and 52 weeks Percentage of patients achieving HbA1c <7.0% at Weeks 12 and 52 Weight change from baseline to Week 12,52 Body composition change from baseline to Week 12,52 Change in grip strength from baseline to Week 12,52 Change in total energy intake and intake of the three macronutrients (FFQ) from baseline to Weeks 12 and 52 Change in urinary albumin (or urinary protein if diabetic nephropathy stage 3 or later) from baseline to Weeks 12 and 52

—

Contacts

Public ContactSodai Kubota

Gifu University Graduate School of Medicine

sodai_0108@yahoo.co.jp+81-582306377

Outcome results